Cubist Systematic Strategies LLC purchased a new position in Portola Pharmaceuticals Inc (NASDAQ:PTLA) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 4,039 shares of the biopharmaceutical company’s stock, valued at approximately $218,000.
Several other large investors also recently modified their holdings of the stock. BlackRock Inc. increased its stake in Portola Pharmaceuticals by 0.9% during the second quarter. BlackRock Inc. now owns 4,071,966 shares of the biopharmaceutical company’s stock valued at $228,721,000 after purchasing an additional 37,241 shares during the last quarter. State Street Corp increased its stake in Portola Pharmaceuticals by 5.3% during the second quarter. State Street Corp now owns 2,085,838 shares of the biopharmaceutical company’s stock valued at $117,164,000 after purchasing an additional 105,207 shares during the last quarter. JPMorgan Chase & Co. increased its stake in Portola Pharmaceuticals by 3.7% during the third quarter. JPMorgan Chase & Co. now owns 744,702 shares of the biopharmaceutical company’s stock valued at $40,081,000 after purchasing an additional 26,544 shares during the last quarter. Kornitzer Capital Management Inc. KS increased its stake in Portola Pharmaceuticals by 38.7% during the third quarter. Kornitzer Capital Management Inc. KS now owns 727,812 shares of the biopharmaceutical company’s stock valued at $39,324,000 after purchasing an additional 202,925 shares during the last quarter. Finally, Goldman Sachs Group Inc. increased its stake in Portola Pharmaceuticals by 17.2% during the second quarter. Goldman Sachs Group Inc. now owns 688,092 shares of the biopharmaceutical company’s stock valued at $38,650,000 after purchasing an additional 101,046 shares during the last quarter. Institutional investors and hedge funds own 87.25% of the company’s stock.
In other news, Director Henry Ward Wolff sold 12,000 shares of the business’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $47.00, for a total transaction of $564,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 5.50% of the company’s stock.
Portola Pharmaceuticals Inc (NASDAQ PTLA) opened at $52.26 on Wednesday. Portola Pharmaceuticals Inc has a 1-year low of $23.70 and a 1-year high of $67.10. The stock has a market cap of $3,410.00, a price-to-earnings ratio of -12.10 and a beta of 1.21. The company has a current ratio of 8.31, a quick ratio of 8.31 and a debt-to-equity ratio of 0.24.
Portola Pharmaceuticals (NASDAQ:PTLA) last announced its quarterly earnings results on Monday, November 6th. The biopharmaceutical company reported ($1.41) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.49) by $0.08. Portola Pharmaceuticals had a negative net margin of 938.19% and a negative return on equity of 110.46%. The company had revenue of $3.83 million during the quarter, compared to the consensus estimate of $4.71 million. During the same quarter in the previous year, the company posted ($1.64) earnings per share. The company’s revenue for the quarter was down 58.9% compared to the same quarter last year. sell-side analysts expect that Portola Pharmaceuticals Inc will post -4.94 EPS for the current year.
ILLEGAL ACTIVITY NOTICE: This story was originally posted by Markets Daily and is the sole property of of Markets Daily. If you are accessing this story on another publication, it was illegally stolen and republished in violation of U.S. and international copyright legislation. The correct version of this story can be read at https://www.themarketsdaily.com/2018/01/10/cubist-systematic-strategies-llc-invests-218000-in-portola-pharmaceuticals-inc-ptla.html.
Portola Pharmaceuticals Profile
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.